Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs

Sophia Gry Moesgaard, Bo Torkel Falk, Tom Teerlink, Halldóra Hrund Guðmundsdóttir, Sif Sigurðardóttir, Caroline Elisabeth Rasmussen, Lisbeth Høier Olsen

    11 Citations (Scopus)

    Abstract

    Elevations in the plasma concentrations of natriuretic peptides correlate with increased severity of myxomatous mitral valve disease (MMVD) in dogs. This study correlates the severity of MMVD with the plasma concentrations of the biomarkers N-terminal fragment of the pro-brain-natriuretic peptide (NT-proBNP) and its second messenger, cyclic guanosine monophosphate (cGMP). Furthermore, the l-arginine:asymmetric dimethylarginine (ADMA) ratio was measured as an index of nitric oxide availability. The study included 75 dogs sub-divided into five groups based on severity of MMVD as assessed by clinical examination and echocardiography. Plasma NT-proBNP and cGMP concentrations increased with increasing valve dysfunction and were significantly elevated in dogs with heart failure. The cGMP:NT-proBNP ratio decreased significantly in dogs with heart failure, suggesting the development of natriuretic peptide resistance. Although the l-arginine:ADMA ratio decreased with increasingly severe MMVD, this was largely due to the older age of the dogs with heart failure.
    Original languageEnglish
    JournalThe Veterinary Journal
    Volume189
    Issue number3
    Pages (from-to)349-352
    Number of pages4
    ISSN1090-0233
    DOIs
    Publication statusPublished - Sept 2011

    Fingerprint

    Dive into the research topics of 'Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs'. Together they form a unique fingerprint.

    Cite this